Related Experiment Videos
Spotlight on olanzapine in bipolar I disorder
Paul L McCormack1, Lynda R Wiseman
1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
CNS Drugs
|June 21, 2005
Summary
Olanzapine effectively treats acute manic episodes and prevents relapse in bipolar I disorder. While associated with weight gain, it offers low extrapyramidal symptoms, making it a valuable treatment option.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Bipolar I disorder involves acute manic episodes and relapse risk.
- Atypical antipsychotics are key in managing bipolar disorder.
- Olanzapine is approved for acute mania and maintenance therapy.
Purpose of the Study:
- Evaluate the efficacy of oral olanzapine in bipolar I disorder.
- Compare olanzapine's effectiveness against placebo and other treatments.
- Assess olanzapine's role in acute and maintenance treatment phases.
Main Methods:
- Review of clinical studies on oral olanzapine for bipolar I disorder.
- Analysis of efficacy in acute manic episodes and long-term relapse prevention.
- Assessment of safety profile, including weight gain and extrapyramidal symptoms.
Main Results:
- Olanzapine is superior to placebo and comparable to lithium, valproate, haloperidol, and risperidone for acute mania.
- Olanzapine is effective in delaying or preventing relapse, potentially more so than lithium for manic relapse.
- Olanzapine is well-tolerated with a low incidence of extrapyramidal symptoms, despite higher rates of weight gain.
Conclusions:
- Oral olanzapine is a useful first-line or adjunctive treatment for acute manic episodes in bipolar I disorder.
- Olanzapine demonstrates efficacy in long-term maintenance therapy, preventing relapse.
- The favorable side effect profile, particularly low extrapyramidal symptoms, supports olanzapine's role in bipolar disorder management.